The Pugwash Conference Turns 30

On July 7 the Pugwash Conference on Science and World Affairs will be 30 years old. Most international institutions serve their original purpose well for 10-15 years and then decline, but continue to linger on. The more successful the institution, the longer it lingers, perhaps in the hopes that its past successes will be repeated. Pugwash seems to be a case in point. It has already begun to fade away, leaving its goal of complete nuclear disarmament still totally unfulfilled. During its lifetim

Written byFrank Barnaby
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

During its lifetime Pugwash has held 36 large conferences—in capitalist, communist and Third World countries—and a number of smaller, specialized symposia. The next conference will be held this August in Austria. Early conferences discussed the consequences of nuclear, chemical and biological warfare, and disarmament and world security; recently, development issues have been added. The participants in the early years were mainly natural scientists, but later social scientists were encouraged to attend.

Pugwash has active national groups in a number of countries. International activity is organized by the organization's secretary-general, Martin Kaplan, in Geneva, and by Joseph Rotblat, the former secretary-general, in London.

The problem is that Pugwash fails to attract young scientists—a failure that will prove fatal. One reason is that Pugwash has always been an elitist organization. Of the world's 2.5 million research scientists, only about 1,000 have ever been to a Pugwash conference. That's a small number compared ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies